Thinly traded nano cap ContraVir Pharmaceuticals (NASDAQ:CTRV) is up 139% premarket on increased volume in reaction to positive preclinical data on NASH candidate CRV431.
The company says CRV431, an inhibitor of a family of proteins called cyclophilins, significantly decreased the extend of scarring in a second animal (mouse) model of liver fibrosis.
Intercept Pharmaceuticals’ (NASDAQ:ICPT) obeticholic acid was used as a comparator, failing to demonstrate a decrease in fibrosis.
The study was conducted at the Scripps Research Institute.
Development is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.